Weidong Han

Overview

Best Publications

• Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells.

  Zhiwei Zhou;Huabin He;Kun Wang;Xuyan Shi

  931
  Citations

• LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b

  Dongdong Ti;Haojie Hao;Chuan Tong;Jiejie Liu

  678
  Citations

• Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy

  Mengze Lv;Mengze Lv;Meixia Chen;Rui Zhang;Wen Zhang;Wen Zhang

  594
  Citations

• Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia

  Quan-shun Wang;Yao Wang;Hai-yan Lv;Qing-wang Han

  458
  Citations

• New development in CAR-T cell therapy

  Zhenguang Wang;Zhiqiang Wu;Yang Liu;Weidong Han

  400
  Citations

• Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

  Chun-Meng Wang;Zhi-Qiang Wu;Yao Wang;Ye-Lei Guo

  362
  Citations

• Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

  Xiaolei Li;Xiaolei Li;Changshun Shao;Yufang Shi;Weidong Han

  324
  Citations

• Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.

  Hanren Dai;Yao Wang;Xuechun Lu;Weidong Han

  319
  Citations

• Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: identification of a novel role in improving insulin sensitivity.

  Yiling Si;Yali Zhao;Haojie Hao;Jiejie Liu

  302
  Citations

• MSCs: Biological characteristics, clinical applications and their outstanding concerns.

  Yi-Ling Si;Ya-Li Zhao;Hao-Jie Hao;Xiao-Bing Fu

  294
  Citations

• Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

  Kaichao Feng;Yelei Guo;Hanren Dai;Yao Wang

  283
  Citations

• Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.

  Kaichao Feng;Yang Liu;Yelei Guo;Jingdan Qiu

  282
  Citations

• Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

  Hanren Dai;Hanren Dai;Zhiqiang Wu;Hejin Jia;Chuan Tong

  273
  Citations

• CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial.

  Yao Wang;Meixia Chen;Zhiqiang Wu;Chuan Tong

  272
  Citations

• Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.

  Chuan Tong;Yajing Zhang;Yang Liu;Xingyu Ji

  271
  Citations

• TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.

  Na Tang;Chen Cheng;Chen Cheng;Xingying Zhang;Miaomiao Qiao

  268
  Citations

• lncRNAs: insights into their function and mechanics in underlying disorders.

  Xiaolei Li;Zhiqiang Wu;Xiaobing Fu;Weidong Han

  245
  Citations

• Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

  Kai-chao Feng;Ye-lei Guo;Yang Liu;Han-ren Dai

  233
  Citations

• Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.

  Yelei Guo;Kaichao Feng;Yang Liu;Zhiqiang Wu

  231
  Citations

• Genetically engineered T cells for cancer immunotherapy.

  Dan Li;Xue Li;Wei-Lin Zhou;Yong Huang

  218
  Citations